Co-Diagnostics Q2 revenue jumps to $2.7M, net loss narrows to $7.6M, submits 510(k) for PCR platform

Co-Diagnostics, Inc.

2024-Q2 EPS reported -$0.56 revenue$3,124,694

Revenue of $2.7M vs $0.2M in prior year, driven by milestone achievements on grants.
Net loss of $7.6M ($0.25/share) improved from $8.9M ($0.31/share) YoY; adjusted EBITDA loss of $5.9M.
Operating loss of $7.7M compared to $12.0M in 2023; cash and securities of $44.9M as of June 30.
Submitted first 510(k) for Co-Dx PCR Pro platform with OTC COVID-19 test to FDA.
Opened new manufacturing facility in South Salt Lake for Co-Primers and PCR platform components.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.